Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases

Reversing inflammatory lung disease remains the foremost challenge in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease. Reducing (or modifying) the underlying inflammatory process with mono-target drugs has proven challenging. The era of designing 'one targ...

Full description

Saved in:
Bibliographic Details
Published inFuture medicinal chemistry Vol. 3; no. 13; p. 1647
Main Authors Ferrari, Nicolay, Seguin, Rosanne, Renzi, Paolo
Format Journal Article
LanguageEnglish
Published England 01.10.2011
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Reversing inflammatory lung disease remains the foremost challenge in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease. Reducing (or modifying) the underlying inflammatory process with mono-target drugs has proven challenging. The era of designing 'one target for one disease' has evolved such that a growing body of evidence suggests a single drug that is capable of specifically targeting multiple targets and pathways would be better at arresting progression of these respiratory diseases and be an important advancement in current therapy. Oligonucleotide-based drugs represent an emerging class of drug candidates. Their properties, a broader range of targets over conventional small-molecule drugs and recent clinical proof-of-concept support their development as novel multi-targeting agents for the treatment of respiratory diseases.
ISSN:1756-8927
DOI:10.4155/FMC.11.108